TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ENTERAL FEEDING FORMULA MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET CHALLENGE MATRIX
2.8 SECONDARY SOURCES
2.9 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING NUMBER OF PRETERM BIRTH
3.1.2 GROWING NUMBER OF CHRONIC DISEASES
3.1.3 GROWING BUSINESS EXPANSION FOR NUTRITIONAL SUPPLY
3.1.4 GROWING NEED OF NUTRITIONAL CARE FOR GERIATRIC POPULATION
3.2 RESTRAINTS
3.2.1 RISK ASSOCIATED WITH THE ENTERAL TUBE FEEDING
3.2.2 STRICT REGULATION OF USAGE FOR PATIENTS SAFETY
3.3 OPPORTUNITIES
3.3.1 GROWTH IN HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES
3.4 CHALLENGES
3.4.1 INSUFFICIENT REIMBURSEMENTS POLICIES
3.4.2 LACK OF TRAINED STAFF
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EUROPE ENTERAL FEEDING FORMULA MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 STANDARD FORMULAS
6.2.1 MONOMERIC
6.2.2 POLYMERIC
6.3 DISEASE SPECIFIC
6.3.1 DIABETIC FORMULAS
6.3.2 RENAL FORMULAS
6.3.3 HEPATIC FORMULAS
6.3.4 PULMONARY FORMULAS
6.3.5 OTHERS
7 EUROPE ENTERAL FEEDING FORMULA MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 CRITICAL CARE
7.3 GASTROENTEROLOGY
7.4 ONCOLOGY
7.5 NEUROLOGY
7.6 DIABETES
7.7 OTHERS
8 EUROPE ENTERAL FEEDING FORMULA MARKET, BY TYPE OF TUBE FEEDING
8.1 OVERVIEW
8.2 GASTRIC TUBE FEEDING
8.3 NASOGASTRIC TUBE FEEDING
8.4 GASTROTOMY TUBE FEEDING
8.5 DUODENAL OR JEJUNAL TUBE FEEDING
9 EUROPE ENTERAL FEEDING FORMULA MARKET, BY STAGE
9.1 OVERVIEW
9.2 ADULT
9.3 PEDIATRIC
10 EUROPE ENTERAL FEEDING FORMULA MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 LONG TERM CARE FACILITIES
10.3.1 HOME CARE AGENCIES AND HOSPICES
10.3.2 NURSING HOMES
10.3.3 ASSISTED LIVING FACILITIES
11 EUROPE ENTERAL FEEDING FORMULA MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 U.K.
11.1.3 FRANCE
11.1.4 SPAIN
11.1.5 ITALY
11.1.6 SWITZERLAND
11.1.7 NETHERLAND
11.1.8 NORWAY
11.1.9 BELGIUM
11.1.10 RUSSIA
11.1.11 POLAND
11.1.12 TURKEY
11.1.13 REST OF EUROPE
12 EUROPE ENTERAL FEEDING FORMULA MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS; EUROPE
13 COMPANY PROFILE
13.1 ABBOTT
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 NESTL?
13.2.1 COMPANY OVERVIEW
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 MEIJI HOLDINGS CO., LTD.
13.3.1 COMPANY OVERVIEW
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
?
13.4 B. BRAUN MELSUNGEN AG
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENTS
13.5 DANONE NUTRICIA
13.5.1 COMPANY SNAPSHOT
13.5.2 GEOGRAPHICAL PRESENCE
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 FRESENIUS SE & CO. KGAA
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 EUROPE HEALTH PRODUCTS, INC.
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENT
13.8 HORMEL FOODS, LLC
13.8.1 COMPANY SNAPSHOT
13.8.2 GEOGRAPHICAL PRESENCE
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 MEAD JOHNSON & COMPANY, LLC.
13.9.1 COMPANY SNAPSHOT
13.9.2 GEOGRAPHICAL PRESENCE
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.10 MEDLINE INDUSTRIES, INC
13.10.1 COMPANY SNAPSHOT
13.10.2 GEOGRAPHICAL PRESENCE
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENTS
13.11 MEDTRITION, INC.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 NO RECENT DEVELOPMENTS
?
13.12 NUTRITIONAL MEDICINALS, LLC
13.12.1 COMPANY SNAPSHOT
13.12.2 GEOGRAPHICAL PRESENCE
13.12.3 PRODUCT PORTFOLIO
13.12.4 NO RECENT DEVELOPMENTS
13.13 REAL FOOD BLENDS
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.14 VICTUS
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENTS
14 RELATED REPORTS